Skip to main content

Advertisement

SpringerLink
Log in

Testosterone and Cardiovascular Diseases: Causes or Consequences: The Lesson from the Last 5 Years

  • Medical Comorbidities (M Miner, S Parish and A Goldstein, Section Editors)
  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

The relationship between the age-dependent decline of testosterone (T) and cardiovascular (CV) risk in men is still a matter of intense debate. In particular, over the last 5 years, several scientific reports have shed a new negative light on the association between T treatment (TTh) and forthcoming CV diseases (CVD). Based on this evidence, the US Food and Drug Administration agency has recommended that all T supplementations carry a warning that they may increase the risk of heart attack and stroke. To better clarify the available data on this topic, we scrutinized and summarized, also by using meta-analytic methods, the data generated during the last 5 years, as derived from the analysis of observational (either longitudinal or pharmaco-epidemiological) studies and from randomized controlled trials (RCTs) on TTh and CVD risk.

Recent Findings

Our analysis shows that there is a clear association between baseline T deficiency and overall mortality and CVD-related mortality when longitudinal surveys were analyzed, although a specific pathogenetic link cannot be made. When interventional trials were studied, several but not all pharmaco-epidemiological studies reported a possible protective role of TTh on CV risk; however, data from RCTs and their meta-analysis, presented here, do not provide us with sufficient information on this point.

Summary

Present data do not indicate an increased risk with TTh, but there is also insufficient definitive evidence that TTh is protective. Therefore, further and more specific trials are advisable to better clarify the possible relationship between low T, TTh, and CVD in aging men.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance

  1. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124:2145–54.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Humphries SE. Common variants for cardiovascular disease. Circulation. 2017;135:2102–5.

    Article  PubMed  Google Scholar 

  3. Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35:341–75.

    Article  CAS  PubMed  Google Scholar 

  4. Velho I, Fighera TM, Ziegelmann PK, Spritzer PM. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology. 2017; https://doi.org/10.1111/andr.12382.

  5. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–7.

    Article  PubMed  Google Scholar 

  6. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.

    Article  CAS  PubMed  Google Scholar 

  7. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75.

    Article  PubMed  Google Scholar 

  8. FDA Drug Safety Communication: FDA cautions about using T products for low T due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htmforHumanMedicalProducts/ucm402054.htm. Published March 3, 2015 (Accessed August 3, 2017).

  9. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687–701.

    Article  CAS  PubMed  Google Scholar 

  10. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab. 2012;97:179–89.

    Article  CAS  PubMed  Google Scholar 

  11. Lerchbaum E, Pilz S, Boehm BO, et al. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol (Oxf). 2012;77:475–83.

    Article  CAS  Google Scholar 

  12. Schneider HJ, Wallaschofski H, Völzke H, et al. Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS One. 2012;7:e33084.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Haring R, Teng Z, Xanthakis V, et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf). 2013;78:629–34.

    Article  CAS  Google Scholar 

  14. Bello AK, Stenvinkel P, Lin M, et al. Serum testosterone levels and clinical outcomes in male hemodialysis patients. Am J Kidney Dis. 2014;63:268–75.

    Article  CAS  PubMed  Google Scholar 

  15. Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV Jr, Shoskes DA. Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis. 2014;64:367–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab. 2014;99:1357–66.

    Article  CAS  PubMed  Google Scholar 

  17. Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99:2061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Srinath R, Hill Golden S, Carson KA, Dobs A. Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study. J Clin Endocrinol Metab. 2015;100:1602–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cheung KK-T, Lau ES-H, So W-Y, Ma RC-W, Ozaki R, Kong AP-S, et al. Low testosterone and clinical outcomes in Chinese men with type 2 diabetes mellitus—Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2017;123:97–105.

    Article  CAS  PubMed  Google Scholar 

  20. Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75:282–8.

    Article  CAS  PubMed  Google Scholar 

  21. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97:870–5.

    Article  CAS  PubMed  Google Scholar 

  22. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39:82–91.

    Article  PubMed  Google Scholar 

  24. Corona G, Cipriani S, Rastrelli G, Sforza A, Mannucci E, Maggi M. High triglycerides predicts arteriogenic erectile dysfunction and major adverse cardiovascular events in subjects with sexual dysfunction. J Sex Med. 2016;13:1347–58.

    Article  PubMed  Google Scholar 

  25. Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120–33.

    Article  CAS  PubMed  Google Scholar 

  26. Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One. 2014;9:e100409.

    Article  PubMed  PubMed Central  Google Scholar 

  27. •• Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174:R99–116. Important meta-analysis summarizing the effect of testosterone treatment on body composition and metabolic profile.

    Article  CAS  PubMed  Google Scholar 

  28. Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15:1903–26.

    Article  CAS  PubMed  Google Scholar 

  29. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Investig. 2016;39:967–81.

    Article  CAS  Google Scholar 

  30. Corona G, Maseroli E, Rastrelli G, Francomano D, Aversa A, Hackett GI, et al. Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol. 2016;41:196–210.

    PubMed  Google Scholar 

  31. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J. 2009;276:5755–67.

    Article  CAS  PubMed  Google Scholar 

  32. Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol. 2014;382:107–19.

    Article  CAS  PubMed  Google Scholar 

  33. Veldhuis J, Yang R, Roelfsema F, Takahashi P. Proinflammatory cytokine infusion attenuates LH’s feedforward on testosterone secretion: modulation by age. J Clin Endocrinol Metab. 2016;101:539–49.

    Article  PubMed  Google Scholar 

  34. Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, et al. Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med. 2011;8:2098–105.

    Article  PubMed  Google Scholar 

  35. Corona G, Rastrelli G, Maseroli E, Fralassi N, Sforza A, Forti G, et al. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology. 2014;2:741–7.

    Article  CAS  PubMed  Google Scholar 

  36. Bartalena L, Bogazzi F, Brogioni S, Grasso L, Martino E. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol. 1998;138:603–14.

    Article  CAS  PubMed  Google Scholar 

  37. • Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36. Pharmaco-epidemiological study empathizing possible increased cardiovascular risk related to testosterone treatment.

    Article  CAS  PubMed  Google Scholar 

  38. • Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Gong Y., editor PLoS One 2014; 9:e85805. Pharmaco-epidemiological study empathizing possible increased cardiovascular risk related to testosterone treatment.

  39. Corona G, Maggi M. Testosterone supplementation and cardiovascular risk. Trends Cardiovasc Med. 2015;25:258–60.

    Article  CAS  PubMed  Google Scholar 

  40. Katz J, Nadelberg R. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311:963.

    Article  CAS  PubMed  Google Scholar 

  41. Riche DM, Baker WL, Koch CA. Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014;311:963.

    Article  CAS  PubMed  Google Scholar 

  42. Irwin G. Knowledge is power. J Sex Med. 2014;11:613–5.

    Article  PubMed  Google Scholar 

  43. Page ST. Testosterone, cardiovascular disease, and mortality in men: living in the dark. Lancet Diabetes Endocrinol. 2014;2:609–11.

    Article  PubMed  Google Scholar 

  44. Morgentaler A. Testosterone, cardiovascular risk, and hormonophobia. J Sex Med. 2014;11:1362–6.

    Article  PubMed  Google Scholar 

  45. Corona G, Dicuio M, Rastrelli G, Maseroli E, Lotti F, Sforza A, et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Investig Med. 2017;65:964–73.

    Article  CAS  PubMed  Google Scholar 

  46. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–8.

    Article  CAS  PubMed  Google Scholar 

  47. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–33.

    Article  CAS  PubMed  Google Scholar 

  48. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Eisenberg ML, Li S, Herder D, Lamb DJ, Lipshultz LI. Testosterone therapy and mortality risk. Int J Impot Res. 2015;27:46–8.

    Article  CAS  PubMed  Google Scholar 

  50. Etminan M, Skeldon SC, Goldenberg SL, Carleton B, Brophy JM. Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study. Pharmacotherapy. 2015;35:72–8.

    Article  CAS  PubMed  Google Scholar 

  51. Ramasamy R, Scovell J, Mederos M, Ren R, Jain L, Lipshultz L. Association between testosterone supplementation therapy and thrombotic events in elderly men. Urology. 2015;86:283–5.

    Article  PubMed  PubMed Central  Google Scholar 

  52. • Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15. Pharmaco-epidemiological study empathizing possible reduced cardiovascular risk related to testosterone treatment.

    Article  PubMed  Google Scholar 

  53. Tan RS, Cook KR, Reilly WG. Myocardial infarction and stroke risk in young healthy men treated with injectable testosterone. Int J Endocrinol. 2015;2015:970750.

    PubMed  PubMed Central  Google Scholar 

  54. Maggi M, Wu FC, Jones TH, et al. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. 2016;70:843–52.

    Article  CAS  PubMed  Google Scholar 

  55. Wallis CJ, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4:498–506.

    Article  CAS  PubMed  Google Scholar 

  56. Cheetham TC, An J, Jacobsen SJ, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177:491–9.

    Article  PubMed  Google Scholar 

  57. Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharmacol Ther. 2017;22(5):414–33.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Jasuja GK, Bhasin S, Reisman JI, Hanlon JT, Miller DR, Morreale AP, et al. Who gets testosterone? Patient characteristics associated with testosterone prescribing in the veteran affairs system: a cross-sectional study. J Gen Intern Med. 2017;32:304–11.

    Article  PubMed  Google Scholar 

  59. Rastrelli G, Giovannini L, Calogero AE, Gianfrilli D, Serra E, Pizzocaro A, et al. Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry. J Endocrinol Investig. 2016;39:695–708.

    Article  CAS  Google Scholar 

  60. Testosterone and Aging: Clinical Research Directions. Institute of Medicine (US) Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy; Liverman CT, Blazer DG, editors. Washington (DC): National Academies Press (US); 2004.

  61. • Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708–16. Important double-blind placebo-controlled trial reporting increased coronary plaque volume related to testosterone treatment.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels. JAMA. 2015;314:570.

    Article  CAS  PubMed  Google Scholar 

  63. •• Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes Endocrinol. 2016;4:943–56. Summary of the available meta-analyses summarizing the effect of testosterone treatment of cardiovascular risk.

    Article  CAS  PubMed  Google Scholar 

  64. Corona G, Sforza A, Maggi M. Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health. 2017;35(2):65–76.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–51.

    Article  CAS  PubMed  Google Scholar 

  67. Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014;12:211.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol. 2016;85:436–43.

    Article  CAS  Google Scholar 

  69. Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med. 2017;130:293–305.

    Article  CAS  PubMed  Google Scholar 

  70. Chillaron JJ, Fernandez-Mirò M, Albareda M, Sara F, Colom C, Vila L, et al. Testosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotropic hypogonadism. Endocr J. 2016;63:849–55.

    Article  PubMed  Google Scholar 

  71. Brock G, Heiselman D, Maggi M, Kim SW, Rodríguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195:699–705.

    Article  CAS  PubMed  Google Scholar 

  72. Glintborg D, Christensen LL, Kvorning T, Larsen R, Højlund K, Brixen K, et al. Differential effects of strength training and testosterone treatment on soluble CD36 in aging men: possible relation to changes in body composition. Scand J Clin Lab Invest. 2015;75:659–66.

    PubMed  Google Scholar 

  73. Cherrier MM, Anderson K, Shofer J, Millard S, Matsumoto AM. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. Am J Alzheimers Dis Other Demen. 2015;30:421–30.

    Article  CAS  PubMed  Google Scholar 

  74. Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167:531–41.

    Article  CAS  PubMed  Google Scholar 

  75. Behre HM, Tammela TL, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012;15:198–207.

    Article  CAS  PubMed  Google Scholar 

  76. Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10:1612–27.

    Article  CAS  PubMed  Google Scholar 

  77. Hildreth KL, Barry DW, Moreau KL, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab. 2013;98:1891–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Maggio M, Snyder PJ, Ceda GP, et al. Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology. 2013;1:24–8.

    Article  CAS  PubMed  Google Scholar 

  79. Borst SE, Yarrow JF, Conover CF, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014;306:E433–42.

    Article  CAS  PubMed  Google Scholar 

  80. Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37:2098–107.

    Article  CAS  PubMed  Google Scholar 

  81. Janjgava S, Zerekidze T, Uchava L, Giorgadze E, Asatiani K. Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency. Eur J Med Res. 2014;19:56.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Asih PR, Wahjoepramono EJ, Aniwiyanti V, et al. Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety. CNS Neurol Disord Drug Targets. 2015;14:576–86.

    Article  CAS  PubMed  Google Scholar 

  83. Basaria S, Travison TG, Alford D, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156:280–8.

    Article  CAS  PubMed  Google Scholar 

  84. Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100:2956–62.

    Article  CAS  PubMed  Google Scholar 

  85. Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39:82–91.

    Article  PubMed  Google Scholar 

  86. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Unit, Medical Department, Azienda Usl, Maggiore-Bellaria Hospital, Bologna, Italy

    Giovanni Corona & Alessandra Sforza

  2. Sexual Medicine and Andrology Unit Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy

    Giulia Rastrelli & Mario Maggi

  3. Urology Unit, Surgical Department, Azienda Usl, Maggiore-Bellaria Hospital, Bologna, Italy

    Mauro Dicuio

Authors
  1. Giovanni Corona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulia Rastrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mauro Dicuio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandra Sforza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mario Maggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Maggi.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article contains no studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Medical Comorbidities

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corona, G., Rastrelli, G., Dicuio, M. et al. Testosterone and Cardiovascular Diseases: Causes or Consequences: The Lesson from the Last 5 Years. Curr Sex Health Rep 9, 277–289 (2017). https://doi.org/10.1007/s11930-017-0132-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-017-0132-3

Keywords

Search

Navigation